Interested in the next generation of weight-loss medications?

Register your interest to receive updates on:

* Oral Semaglutide (Novo Nordisk)
* Orforglipron (Eli Lilly)

These investigational weight-loss tablets are expected to offer an alternative to injectable treatments such as Wegovy and Mounjaro, subject to regulatory approval.

Be among the first to receive updates on:

* UK availability and launch dates
* Pricing information
* Eligibility criteria
* Clinical and regulatory developments

Leave your details below to join the waiting list.

There is no obligation to purchase. We will only contact you with relevant updates regarding these treatments.